Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Patients with chronic myeloid leukemia (CML) receiving 800mg of Glivec are more likely to attain complete cytogenetic response compared to the standard dose of 400mg. If these preliminary results translate into improved survival for CML patients then this will undoubtedly secure further revenue for Novartis [NVS] as physicians switch to high dose Glivec.
Published By Datamonitor
|
07 Dec 2004 |
|
CommentWire
|
Positive trial data for Avastin drove Genentech's [DNA] share price up by almost 25% and parent company Roche's [ROCZ.S] share price by over 5%. Roche and Genentech have partnered to form the largest global player for cancer drugs, and Avastin looks set to provide them with another superstar product. Genentech's future as a major biotech player in the cancer market thus seems assured.
Published By Datamonitor
|
16 Mar 2005 |
|
Expert View
|
Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).
Published By Datamonitor
|
09 Jun 2005 |
|
CommentWire
|
Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.
Published By Datamonitor
|
20 Jul 2005 |
|
Expert View
|
Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...
Published By Datamonitor
|
02 Aug 2005 |
|
CommentWire
|
Chiron has snubbed Novartis' offer to acquire the remaining shares of the company that it does not already own, calling the offer "inadequate". Chiron no doubt wants to hold out for a better offer, which is a wise move since, as Novartis will be the key benefactor from the takeover, the Swiss company is likely to significantly increase its bid.
Published By Datamonitor
|
07 Sep 2005 |
|
CommentWire
|
Avalon Pharmaceuticals and Novartis have entered into a collaboration to discover small molecule therapeutic compounds using Avalon's AvalonRx drug discovery engine. AvalonRx has been key to past collaborative agreements with large biotech and pharma companies such as MedImmune and Sanofi-Aventis, but with Avalon's imminent public offering of stock, the Novartis deal could be more significant.
Published By Datamonitor
|
14 Sep 2005 |
|
CommentWire
|
Novartis has finally satisfied Chiron's board after raising its takeover bid for the firm. This is good, if unsurprising, news for Novartis, as Chiron offers the Swiss drug maker growth opportunities in vaccines and biopharmaceuticals. Indeed, despite its recent woes, Chiron should be a good buy, enabling Novartis to become a key player in the increasingly important vaccine market.
Published By Datamonitor
|
02 Nov 2005 |
|
CommentWire
|
Novartis and Alnylam have joined to advance pandemic flu therapeutics based on RNAi through initial clinical testing and eventually regulatory approval. This focus on RNAi R&D is driven by fears that current flu vaccines and antivirals might not be sufficient to protect against the H5N1 pandemic strain and only time will tell whether an approval is granted before the impending pandemic strikes.
Published By Datamonitor
|
21 Feb 2006 |
|
CommentWire
|
Novartis stands on the brink of launching the first innovative treatment for hypertension in over a decade, in the form of Rasilez (aliskiren), thanks to the efforts of the drug's development partner, Speedel. This vindicates the risk Speedel took back in 1998 when it set out to build a business based on big pharma cast-offs, something many believed was doomed to fail.
Published By Datamonitor
|
10 Mar 2006 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.